Edward Tuddenham

List of Publications by Year
in descending order

236 papers	18,152 citations	16451 64 h-index	13379 130 g-index
239 all docs	239 docs citations	239 times ranked	10221 citing authors

#	Article	IF	Citations
1	Factor VIII: the protein, cloning its gene, synthetic factor and now â€“ 35Âyears later â€“ gene therapy; what happened in between?. British Journal of Haematology, 2020, 189, 400-407.	2.5	6
2	Global coagulation assays in hemophilia A: A comparison to conventional assays. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 298-308.	2.3	12
3	Interaction Between the a3 Region of Factor VIII and the TILâ€™Eâ€™ Domains of the von Willebrand Factor. Biophysical Journal, 2019, 117, 479-489.	0.5	9
4	Recent advances in developing specific therapies for haemophilia. British Journal of Haematology, 2018, 181, 161-172.	2.5	32
5	A Single Intravenous Infusion of FLT180a Results in Factor IX Activity Levels of More Than 40% and Has the Potential to Provide a Functional Cure for Patients with Haemophilia B. Blood, 2018, 132, 631-631.	1.4	13
6	GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. Blood, 2018, 132, 489-489.	1.4	36
7	Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer. Blood, 2018, 132, 491-491.	1.4	77
8	Advances in Gene Therapy for Hemophilia. Human Gene Therapy, 2017, 28, 1004-1012.	2.7	54
9	Gene Therapy for Hemophilia. Hematology/Oncology Clinics of North America, 2017, 31, 853-868.	2.2	30
10	Platelets are a safe way to deliver factor VIII. After 13 years of preclinical research it is now time for a clinical trial. Journal of Thrombosis and Haemostasis, 2017, 15, 96-97.	3.8	2
11	First steps in the standardization of immunoglobulin IgG myeloperoxidaseâ€antiâ€neutrophil cytoplasmic antibody measurements. Clinical and Experimental Immunology, 2016, 183, 193-205.	2.6	6
12	Novel, human cell lineâ€derived recombinant factor VIII (humanâ€cl rhFVIII; Nuwiq^{Â®}) in adults with severe haemophilia A: efficacy and safety. Haemophilia, 2016, 22, 225-231.	2.1	34
13	The impact of sport on health status, psychological wellâ€being and physical performance of adults with haemophilia. Haemophilia, 2016, 22, 521-530.	2.1	32
14	Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring. British Journal of Haematology, 2015, 168, 719-727.	2.5	29
15	Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. New England Journal of Medicine, 2014, 371, 1994-2004.	27.0	1,063
16	Far away and long ago. Journal of Thrombosis and Haemostasis, 2014, 12, 34-35.	3.8	1
17	In search of the source of factor VIII. Blood, 2014, 123, 3691-3691.	1.4	4
18	Solution structure of the major factor VIII binding region on von Willebrand factor. Blood, 2014, 123, 4143-4151.	1.4	41

#	Article	IF	Citations
19	An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. Journal of Thrombosis and Haemostasis, 2013, 11, 1329-1340.	3.8	138
20	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013, 121, 3335-3344.	1.4	236
21	Cellular Immune Responses To Vector In a Gene Therapy Trial For Hemophilia B Using An AAV8 Self-Complementary Factor IX Vector. Blood, 2013, 122, 717-717.	1.4	0
22	Haemophilic pseudotumour of the carotid artery. Vascular Medicine, 2012, 17, 193-194.	1.5	2
23	"Magic" mushrooms don't cause renal failure. BMJ, The, 2012, 345, e6893-e6893.	6.0	0
24	AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood, 2012, 119, 957-966.	1.4	44
25	Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia, 2012, 18, 241-245.	2.1	39
26	Gene therapy for haemophilia B. Haemophilia, 2012, 18, 13-17.	2.1	19
27	Genetics of haemostasis. Haemophilia, 2012, 18, 73-80.	2.1	9
28	Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardianâ„¢ Trials.. Blood, 2012, 120, 2228-2228.	1.4	1
29	Stable Factor IX Activity Following AAV-Mediated Gene Transfer in Patients with Severe Hemophilia B. Blood, 2012, 120, 752-752.	1.4	2
30	Adenovirus-Associated Virus Vectorâ€“Mediated Gene Transfer in Hemophilia B. New England Journal of Medicine, 2011, 365, 2357-2365.	27.0	1,606
31	Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood, 2011, 117, 798-807.	1.4	163
32	Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood, 2011, 117, 3684-3691.	1.4	232
33	Human Congenital Diseases with Mixed Modes of Inheritance Have a Shortage of Recessive Disease. A Demographic Scenario?. Annals of Human Genetics, 2011, 75, 688-693.	0.8	6
34	Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thrombosis and Haemostasis, 2011, 106, 521-527.	3.4	39
35	Enhanced thrombin generation in patients with cirrhosisâ€induced coagulopathy. Journal of Thrombosis and Haemostasis, 2010, 8, 1994-2000.	3.8	170
36	Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia, 2010, 16, 584-591.	2.1	71

#	Article	IF	Citations
37	Menorrhagia in Adolescents with Inherited Bleeding Disorders. Journal of Pediatric and Adolescent Gynecology, 2010, 23, 215-222.	0.7	86
38	Assessing the Potential of Perinatal Gene Transfer Using Congenital Factor VII Deficiency as a Model System. Blood, 2010, 116, 247-247.	1.4	1
39	Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B. Blood, 2010, 116, 248-248.	1.4	19
40	Stable High Level Coagulation Factor VIII Expression In Vivo Following Gene Transfer Using a Novel Expression Cassette Encoding a More Potent FVIII Variant. Blood, 2010, 116, 250-250.	1.4	4
41	Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven^{Â®}] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia, 2009, 15, 501-508.	2.1	77
42	Optimizing warfarin reversal â€“ an exÂvivo study. Journal of Thrombosis and Haemostasis, 2009, 7, 1123-1127.	3.8	29
43	Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. Thrombosis and Haemostasis, 2009, 102, 287-301.	3.4	30
44	P53 Menorrhagia in adolescents with inherited bleeding disorders. Thrombosis Research, 2009, 123, S155.	1.7	0
45	Anticoagulation after liver transplantation: a retrospective audit and caseâ€“control study. Blood Coagulation and Fibrinolysis, 2009, 20, 615-618.	1.0	5
46	Â1-antitrypsin Pittsburgh in a family with bleeding tendency. Haematologica, 2009, 94, 881-884.	3.5	26
47	Therapeutic shoulder arthroscopy in patients with clotting disorders. Haemophilia, 2008, 14, 859-861.	2.1	6
48	Genetic aspects and research development in haemostasis. Haemophilia, 2008, 14, 113-118.	2.1	3
49	Consideration of platelet function disorders in patients with reduced VWF levels. Haemophilia, 2008, 14, 1131-1132.	2.1	1
50	The varieties of von Willebrand's disease. International Journal of Laboratory Hematology, 2008, 6, 307-323.	0.2	22
51	Endogenous heparinoids contribute to coagulopathy in patients with liver disease. Journal of Hepatology, 2008, 48, 371-372.	3.7	16
52	Coagulation and fibrosis in chronic liver disease. Gut, 2008, 57, 1722-1727.	12.1	58
53	Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood, 2008, 111, 5592-5600.	1.4	63
54	Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2Î± mutation. Blood, 2008, 112, 919-921.	1.4	143

#	Article	IF	Citations
55	Killing 2 birds with 1 stone. Blood, 2008, 112, 2595-2595.	1.4	1
56	Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 2007, 109, 1414-1421.	1.4	246
57	Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing. Thrombosis Research, 2007, 120, 135-139.	1.7	9
58	17 Levonorgestrel-releasing intrauterine system for the management of menorrhagia in women with inherited bleeding disorders: Long term follow-up. Thrombosis Research, 2007, 119, S101.	1.7	6
59	Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A. Thrombosis and Haemostasis, 2006, 95, 373-379.	3.4	37
60	Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood, 2006, 107, 1903-1907.	1.4	111
61	Factor VIII: purer is not necessarily better. Blood, 2006, 107, 4-5.	1.4	4
62	Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. Journal of Thrombosis and Haemostasis, 2006, 4, 2191-2198.	3.8	19
63	Detection of functional differences between different platelet membrane glycoprotein IbÂ variable number tandem repeat and Kozak genotypes as shown by the PFA-100 system. Heart, 2006, 92, 676-678.	2.9	7
64	Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006, 107, 2653-2661.	1.4	366
65	Ways to bypass a blocked tenase complex. Thrombosis and Haemostasis, 2006, 95, 1-2.	3.4	1
66	A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood, 2005, 106, 542-549.	1.4	89
67	Gene therapy for hemophilia?. Journal of Thrombosis and Haemostasis, 2005, 3, 1314-1314.	3.8	7
68	Lipogranuloma of the breast due to phenothiazine therapy. British Journal of Surgery, 2005, 57, 76-79.	0.3	4
69	Characterisation of blood coagulation factor XIT475I. Thrombosis and Haemostasis, 2005, 93, 1082-1088.	3.4	11
70	A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier syndrome (BSS). Thrombosis and Haemostasis, 2005, 94, 599-605.	3.4	21
71	Factor VII and cardiovascular risk. Thrombosis and Haemostasis, 2005, 93, 189-189.	3.4	0
72	Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thrombosis and Haemostasis, 2005, 93, 23-26.	3.4	115

#	Article	IF	Citations
73	Characterisation of lymphocyte responses to Ca2+ in Scott syndrome. Thrombosis and Haemostasis, 2004, 91, 412-415.	3.4	10
74	35. Downregulation of Immune Responses Induced by Oral DNA Administration. Molecular Therapy, 2004, 9, S15.	8.2	0
75	Two novel mutations in severe factor VII deficiency. British Journal of Haematology, 2004, 126, 105-110.	2.5	9
76	Prospects for gene therapy of haemophilia. Haemophilia, 2004, 10, 309-318.	2.1	54
77	Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 2004, 427, 537-541.	27.8	1,039
78	Complete Inhibition of Acute Humoral Rejection Using Regulated Expression of Membrane-tethered Anticoagulants on Xenograft Endothelium. American Journal of Transplantation, 2004, 4, 1958-1963.	4.7	93
79	Environmental and genetic factors influencing inhibitor development. Seminars in Hematology, 2004, 41, 82-88.	3.4	147
80	Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood, 2004, 103, 3381-3387.	1.4	50
81	Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood, 2004, 104, 1344-1349.	1.4	49
82	Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood, 2004, 104, 2714-2721.	1.4	132
83	Analysis of the consequences of premature termination codons within factor VIII coding sequences. Journal of Thrombosis and Haemostasis, 2003, 1, 139-146.	3.8	17
84	In search of the eighth factor: a personal reminiscence. Journal of Thrombosis and Haemostasis, 2003, 1, 403-409.	3.8	7
85	450 million years of hemostasis. Journal of Thrombosis and Haemostasis, 2003, 1, 1487-1494.	3.8	143
86	Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. Journal of Thrombosis and Haemostasis, 2003, 1, 1935-1944.	3.8	54
87	Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. British Journal of Haematology, 2003, 123, 496-501.	2.5	46
88	Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nature Genetics, 2003, 34, 220-225.	21.4	282
89	Thromboelastography, whole-blood haemostasis and recurrent miscarriage. Human Reproduction, 2003, 18, 2540-2543.	0.9	76
90	Molecular evolution of the vertebrate blood coagulation network. Thrombosis and Haemostasis, 2003, 89, 420-428.	3.4	88

#	Article	IF	Citations
91	Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. British Heart Journal, 2002, 87, 70-74.	2.1	37
92	Commentary on book review: A History of Blood Coagulation. Haemophilia, 2002, 8, 62-62.	2.1	0
93	Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. British Journal of Haematology, 2002, 118, 839-842.	2.5	16
94	Factor VIII - novel insights into form and function. British Journal of Haematology, 2002, 119, 323-331.	2.5	47
95	RNA as drug and antidote. Nature, 2002, 419, 23-24.	27.8	8
96	Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRMâˆ) and G1948D (CRMr). British Journal of Haematology, 2001, 113, 604-615.	2.5	5
97	Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. Xenotransplantation, 2001, 8, 258-265.	2.8	17
98	Factor VII deficiency and the FVII mutation database. Human Mutation, 2001, 17, 3-17.	2.5	159
99	The Hemophilias â€" From Royal Genes to Gene Therapy. New England Journal of Medicine, 2001, 344, 1773-1779.	27.0	936
100	Gene therapy for the haemophilias. Haemophilia, 2000, 6, 115-119.	2.1	9
101	Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Human Genetics, 2000, 107, 327-342.	3.8	92
102	An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence. Thrombosis and Haemostasis, 2000, 84, 442-448.	3.4	10
103	Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis. Transplantation Proceedings, 2000, 32, 971.	0.6	1
104	O-132. Computerized thromboelastographic parameters amongst women with recurrent miscarriageâ€"evidence for a pro-thrombotic state. Human Reproduction, 1999, 14, 73-73.	0.9	3
105	Crystallization and Preliminary X-Ray Analysis of Active Site-Inhibited Human Coagulation Factor VIIa (des-Gla). Journal of Structural Biology, 1999, 125, 90-93.	2.8	6
106	Crystal Structure of Active Site-Inhibited Human Coagulation Factor VIIa (des-Gla). Journal of Structural Biology, 1999, 127, 213-223.	2.8	77
107	INHIBITION OF TISSUE FACTOR-DEPENDENT AND -INDEPENDENT COAGULATION BY CELL SURFACE EXPRESSION OF NOVEL ANTICOAGULANT FUSION PROTEINS. Transplantation, 1999, 67, 467-474.	1.0	35
108	REGULATED INHIBITION OF COAGULATION BY PORCINE ENDOTHELIAL CELLS EXPRESSING P-SELECTIN-TAGGED HIRUDIN AND TISSUE FACTOR PATHWAY INHIBITOR FUSION PROTEINS. Transplantation, 1999, 68, 832-839.	1.0	42

#	Article	IF	Citations
109	Molecular Biological Aspects of Inhibitor Development. Vox Sanguinis, 1999, 77, 13-16.	1.5	5
110	REGULATED ENDOTHELIAL CELL EXPRESSION OF NOVEL MOLECULES WITH ANTICOAGULANT PROPERTIES: A STRATEGY FOR THE PREVENTION AND THERAPY OF VASCULAR REJECTION. Transplantation, 1999, 67, S117.	1.0	0
111	The genetic basis of inhibitor development in haemophilia A. Haemophilia, 1998, 4, 543-545.	2.1	45
112	Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. British Journal of Haematology, 1998, 100, 773-776.	2.5	84
113	The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Research, 1998, 26, 216-219.	14.5	208
114	Mutation databases on the Web.. Journal of Medical Genetics, 1998, 35, 529-533.	3.2	8
115	Expression of Hirudin Fusion Proteins in Mammalian Cells. Circulation, 1998, 98, 2744-2752.	1.6	31
116	Coagulation Factor VII Gln100 â†' Arg. Journal of Biological Chemistry, 1998, 273, 8516-8521.	3.4	20
117	Science, medicine, and the future: Assessing thrombotic risk. BMJ: British Medical Journal, 1998, 317, 520-523.	2.3	55
118	Methylenetetrahydrofolate Reductase Mutation and Coronary Artery Disease. Circulation, 1998, 98, 2932-2935.	1.6	0
119	Coronary Thrombosis and the Platelet Glycoprotein IIIA Gene PLA2 Polymorphism. Thrombosis and Haemostasis, 1998, 80, 218-219.	3.4	48
120	Haemophilia: does the future lie in replacement therapy or auto-supply?. Journal of the Royal Society of Medicine, 1998, 91, 506-506.	2.0	0
121	Exclusion of the First EGF Domain of Factor VII by a Splice Site Mutation Causes Lethal Factor VII Deficiency. Blood, 1998, 92, 920-926.	1.4	0
122	Inherited thrombophilias. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 375-378.	0.5	6
123	The Factor VIII Mutation Database on the World Wide Web: The Haemophilia A Mutation, Search, Test and Resource Site HAMSTeRS Update (version 3.0). Nucleic Acids Research, 1997, 25, 128-132.	14.5	55
124	The Locus for Combined Factor V-Factor VIII Deficiency (F5F8D) Maps to 18q21, between D18S849 and D18S1103. American Journal of Human Genetics, 1997, 61, 143-150.	6.2	38
125	A Molecular Model for the Triplicated A Domains of Human Factor VIII Based on the Crystal Structure of Human Ceruloplasmin. Blood, 1997, 89, 2413-2421.	1.4	214
126	Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Human Genetics, 1997, 101, 323-332.	3.8	43

#	Article	IF	Citations
127	Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced haemophilia A patients by single-strand conformation polymorphism. British Journal of Haematology, 1997, 98, 901-906.	2.5	9
128	HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII. Thrombosis and Haemostasis, 1997, 77, 238-242.	3.4	163
129	High Prevalence of Elevated Factor VIII Levels in Patients Referred for Thrombophilia Screening: Role of Increased Synthesis and Relationship to the Acute Phase Reaction. Thrombosis and Haemostasis, 1997, 77, 0825-0828.	3.4	196
130	Factor VIII Ise (R2159C) in a Patient with Mild Hemophilia A, an Abnormal Factor VIII with Retention of Function but Modification of C2 Epitopes. Thrombosis and Haemostasis, 1997, 77, 0862-0867.	3.4	25
131	Inherited Factor VII Deficiency: Molecular Genetics and Pathophysiology. Thrombosis and Haemostasis, 1997, 78, 151-160.	3.4	103
132	Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology. Thrombosis and Haemostasis, 1997, 78, 161-172.	3.4	71
133	Human Tissue Factor Pathway Inhibitor Fused to CD4 Binds both FXa and TF/FVIIa at the Cell Surface. Thrombosis and Haemostasis, 1997, 78, 1488-1494.	3.4	19
134	Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood, 1996, 87, 4187-4196.	1.4	57
135	Severe perinatal thrombosis in double and triple heterozygous offspring of a family segregating two independent protein S mutations and a protein C mutation. Blood, 1996, 87, 3731-3737.	1.4	29
136	The Tissue Factor-Factor VII Complex: Recent Advances towards Elucidating the Structure and Function of the Initiator of Haemostasis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 20-24.	0.3	2
137	The haemophilia A mutation search test and resource site, home page of the factor VIII mutation database: HAMSTeRS. Nucleic Acids Research, 1996, 24, 100-102.	14.5	26
138	High Purity Factor IX and Prothrombin Complex Concentrate (PCC): Pharmacokinetics and Evidence that Factor IXa Is the Thrombogenic Trigger in PCC. Thrombosis and Haemostasis, 1996, 76, 023-028.	3.4	33
139	Factor VII_{Shinj}_o: A Dysfunctional Factor VII Variant Homozygous for the Substitution Gln for Arg at Position 79. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1995, 25, 89-97.	0.3	9
140	Identification of two novel mutations in non-Jewish factor XI deficiency. British Journal of Haematology, 1995, 90, 916-920.	2.5	40
141	Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. British Journal of Haematology, 1995, 91, 458-464.	2.5	58
142	Molecular etiology of factor VIII deficiency in hemophilia A. Human Mutation, 1995, 5, 1-22.	2.5	123
143	INCREASE OF ACTIVATED FACTOR VIIA AND HAEMOSTATIC MOLECULAR MARKERS IN JUVENILE CHRONIC ARTHRITIS. Rheumatology, 1995, 34, 466-469.	1.9	12
144	Energetic Contributions and Topographical Organization of Ligand Binding Residues of Tissue Factor. Biochemistry, 1995, 34, 6310-6315.	2.5	49

#	Article	IF	Citations
145	Factor VIIa and the extracellular domains of human tissue factor form a compact complex: A study by X-ray and neutron solution scattering. FEBS Letters, 1995, 374, 141-146.	2.8	16
146	Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation. Thrombosis and Haemostasis, 1995, 74, 1402-1406.	3.4	283
147	Purified factor VIII. BMJ: British Medical Journal, 1995, 311, 465-466.	2.3	3
148	Six point mutations that cause factor XI deficiency. Blood, 1995, 85, 1509-1516.	1.4	54
149	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood, 1995, 86, 2632-2641.	1.4	2
150	A Standard Nomenclature for Factor VIII and Factor IX Gene Mutations and Associated Amino Acid Alterations. Thrombosis and Haemostasis, 1994, 72, 475-476.	3.4	6
151	Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Research, 1994, 22, 3511-3533.	14.5	112
152	A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nature Genetics, 1994, 6, 205-209.	21.4	202
153	Crystal structure of the extracellular region of human tissue factor. Nature, 1994, 370, 662-666.	27.8	230
154	10 Myeloproliferative and metabolic causes. Best Practice and Research: Clinical Haematology, 1994, 7, 591-635.	1.1	6
155	Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII. British Journal of Haematology, 1994, 86, 610-618.	2.5	61
156	Haemophilia A diagnosis by simultaneous analysis of two variable dinucleotide tandem repeats within the factor VIII gene. British Journal of Haematology, 1994, 86, 804-809.	2.5	72
157	Efficient gene transfer into human umbilical vein endothelial cells allows functional analysis of the human tissue factor gene promoter. British Journal of Haematology, 1994, 88, 122-128.	2.5	33
158	High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector. Gene, 1994, 139, 275-279.	2.2	34
159	Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. American Heart Journal, 1994, 127, 607-612.	2.7	157
160	Flip tip inversion and haemophilia A. Lancet, The, 1994, 343, 307-308.	13.7	8
161	Thrombophilia: the new factor is old factor V. Lancet, The, 1994, 343, 1515-1516.	13.7	13
162	Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry, 1994, 33, 14162-14169.	2.5	74

#	Article	IF	Citations
163	Molecular genetics of familial venous thrombosis. British Medical Bulletin, 1994, 50, 833-850.	6.9	8
164	Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single-stranded conformation polymorphism. Blood Coagulation and Fibrinolysis, 1994, 5, 257-264.	1.0	29
165	Flipping the tip of the X. Nature Genetics, 1993, 5, 209-209.	21.4	2
166	Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381 â† Ser) in the substrate-binding pocket. British Journal of Haematology, 1993, 84, 285-289.	2.5	18
167	A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. British Journal of Haematology, 1993, 84, 290-300.	2.5	26
168	Mutations in haemophilia A. British Journal of Haematology, 1993, 83, 450-458.	2.5	23
169	Crystallization and Preliminary X-ray Analysis of Human Tissue Factor Extracellular Domain. Journal of Molecular Biology, 1993, 234, 1263-1265.	4.2	10
170	Thrombophilla: a new factor emerges from the mists. Lancet, The, 1993, 342, 1501-1502.	13.7	17
171	Synthesis and characterization of wild-type and variant .gamma.-carboxyglutamic acid-containing domains of factor VII. Biochemistry, 1993, 32, 13949-13955.	2.5	32
172	Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. Human Molecular Genetics, 1993, 2, 1355-1359.	2.9	30
173	A G â† A substitution in an HNF I binding site in the human Î±-fetoprotein gene is associated with hereditary persistence of Î±-fetoprotein (HPAFP). Human Molecular Genetics, 1993, 2, 379-384.	2.9	70
174	Structural requirements for the interaction between tissue factor and factor VII: characterization of chymotrypsin-derived tissue factor polypeptides. Biochemical Journal, 1993, 292, 7-12.	3.7	14
175	Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood, 1993, 81, 2339-2347.	1.4	2
176	Inactivation of factor VIII by factor IXa. Biochemistry, 1992, 31, 2805-2812.	2.5	51
177	Epidemiology of coagulation disorders. Best Practice and Research: Clinical Haematology, 1992, 5, 383-439.	1.1	58
178	The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding. Thrombosis and Haemostasis, 1992, 68, 464-469.	3.4	14
179	Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene. Lancet, The, 1991, 338, 207-211.	13.7	133
180	Haemophilia A: database of ncleotide substituttions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Research, 1991, 19, 4821-4833.	14.5	123

#	Article	IF	Citations
181	Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood, 1991, 78, 132-140.	1.4	7
182	Axillary vein thrombosis in adolescent onset systemic sclerosis.. Annals of the Rheumatic Diseases, 1990, 49, 557-559.	0.9	6
183	CRM+haemophilia A due to a missense mutation (372â†'Cys) at the internal heavy chain thrombin cleavage site. British Journal of Haematology, 1990, 75, 73-77.	2.5	20
184	Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor XI and Detection of Factor XI in Hep G2 Cell Conditioned Medium. Thrombosis and Haemostasis, 1990, 63, 417-423.	3.4	6
185	Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A. Blood, 1989, 73, 2117-2122.	1.4	37
186	Response to desmopressin in type IID von Willebrand's disease. International Journal of Laboratory Hematology, 1989, 11, 189-197.	0.2	5
187	von Willebrand factor and its disorders: An overview of recent molecular studies. Blood Reviews, 1989, 3, 251-262.	5.7	30
188	BIOPSY OF HUMAN PREIMPLANTATION EMBRYOS AND SEXING BY DNA AMPLIFICATION. Lancet, The, 1989, 333, 347-349.	13.7	428
189	Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. Thrombosis Research, 1989, 53, 475-484.	1.7	55
190	Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII:Ag.. Journal of Clinical Pathology, 1988, 41, 337-341.	2.0	9
191	Characterization of a murine homeo box gene, Hox-2.6, related to the Drosophila Deformed gene.. Genes and Development, 1988, 2, 1424-1438.	5.9	146
192	Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays.. Journal of Clinical Pathology, 1988, 41, 342-345.	2.0	3
193	Mutations of factor VIII cleavage sites in hemophilia A. Blood, 1988, 72, 1022-1028.	1.4	4
194	Haemophilia A: carrier detection and prenatal diagnosis by linkage analysis using DNA polymorphism.. Journal of Clinical Pathology, 1987, 40, 971-977.	2.0	18
195	A monoclonal antibody based immunoradiometric assay for von willebrand factor: Survey of a large patient group. Thrombosis Research, 1987, 45, 101-108.	1.7	3
196	Identification of six functional clotting factor VIII:C epitopes by analysis of cross-reactive public idiotypes in murine monoclonal VIII:C inhibitors. Thrombosis Research, 1987, 45, 527-536.	1.7	12
197	Production of factor VIII deficient plasma by immunodepletion using three monoclonal antibodies. British Journal of Haematology, 1987, 66, 497-502.	2.5	10
198	Studies on immunological assay of vitamin K dependent factors... British Journal of Haematology, 1986, 62, 171-181.	2.5	7

#	Article	IF	Citations
199	Studies on immunological assay of vitamin K dependent factors. British Journal of Haematology, 1986, 62, 183-193.	2.5	18
200	Studies on immunological assay of vitamin-K dependent factors... British Journal of Haematology, 1986, 62, 513-524.	2.5	2
201	A new polymorphism in the factor VIII gene for prenatal diagnosis of hemophilia A. Nucleic Acids Research, 1986, 14, 4535-4542.	14.5	137
202	Haemostatic problems in liver disease.. Gut, 1986, 27, 339-349.	12.1	76
203	Cloned Factor VIII and the Molecular Genetics of Hemophilia. Cold Spring Harbor Symposia on Quantitative Biology, 1986, 51, 365-369.	1.1	2
204	Inherited Bleeding Disorders. International Anesthesiology Clinics, 1985, 23, 61-72.	0.8	5
205	Desmopressin and bleeding time in patients with cirrhosis.. BMJ: British Medical Journal, 1985, 291, 1377-1381.	2.3	98
206	Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene. Nature, 1985, 314, 738-740.	27.8	242
207	Detection and sequence of mutations in the factor VIII gene of haemophiliacs Â. Nature, 1985, 315, 427-430.	27.8	206
208	Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature, 1985, 317, 726-729.	27.8	275
209	The effect of liver disease on factors V, VIII and protein C. British Journal of Haematology, 1985, 61, 541-548.	2.5	30
210	An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope. British Journal of Haematology, 1985, 59, 565-577.	2.5	37
211	Albinism with haemorrhagic diathesis: Hermansky-Pudlak syndrome.. British Journal of Ophthalmology, 1985, 69, 904-908.	3.9	25
212	ANTENATAL DIAGNOSIS AND CARRIER DETECTION OF HAEMOPHILIA A USING FACTOR VIII GENE PROBE. Lancet, The, 1985, 325, 1093-1094.	13.7	34
213	The effect of an acute phase reaction and BCBG innoculation on factor VIII in the guinea-pig. Thrombosis Research, 1985, 40, 445-451.	1.7	6
214	Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. Biochemistry, 1985, 24, 4294-4300.	2.5	137
215	Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood, 1984, 63, 31-41.	1.4	119
216	Expression of active human factor VIII from recombinant DNA clones. Nature, 1984, 312, 330-337.	27.8	698

#	Article	IF	Citations
217	Structure of human factor VIII. Nature, 1984, 312, 337-342.	27.8	869
218	Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. British Journal of Haematology, 1984, 56, 535-543.	2.5	56
219	A CLINICALLY USEFUL DNA PROBE CLOSELY LINKED TO HAEMOPHILIA A. Lancet, The, 1984, 324, 6-8.	13.7	99
220	Disappearance of Antibodies to Factor VIII in a Patient with Acquired Haemophilia and Carcinoma of the Pancreas During Cytotoxic Therapy with Fluorouracil and CCNU. Thrombosis and Haemostasis, 1984, 52, 131-133.	3.4	9
221	A maximum likelihood estimate of the sex ratio of mutation rates in Haemophilia A. Human Genetics, 1983, 64, 156-159.	3.8	40
222	Von Willebrand factor multimer patterns in von Willebrand's disease. British Journal of Haematology, 1983, 55, 493-507.	2.5	67
223	Morphological and functional disturbances of platelets induced by cryopreservation.. Journal of Clinical Pathology, 1982, 35, 870-874.	2.0	9
224	Immunologic studies of factor VIII coagulant activity (VIII:C) 2. Factor VIII in selected vertebrates. Thrombosis Research, 1982, 25, 423-431.	1.7	5
225	Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. British Journal of Haematology, 1982, 52, 259-267.	2.5	178
226	Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. Thrombosis Research, 1981, 21, 431-445.	1.7	40
227	Reactions to low-molecular-weight porcine factor VIII concentrates.. BMJ: British Medical Journal, 1981, 283, 381-382.	2.3	11
228	Synthesis and Release of Factor VIII by Cultured Human Endothelial Cells. British Journal of Haematology, 1981, 47, 617-626.	2.5	67
229	Detachment of Endothelial Cells by Polymorphonuclear Leukocytesin Vitro: Potentiation by Antibody Coating and Prevention by Inflammatory Exudate. Journal of Periodontology, 1981, 52, 668-672.	3.4	6
230	ENDOTHELIAL CELLS AND FACTOR-VIII-RELATED PROTEIN. Lancet, The, 1976, 307, 46.	13.7	6
231	Junior Hospital Doctors' Contract. BMJ: British Medical Journal, 1975, 1, 276-276.	2.3	0
232	Tissue Localization and Synthesis of Factor-VIII-Related Antigen in the Human Foetus. British Journal of Haematology, 1974, 26, 669-677.	2.5	14
233	Hyperviscosity Syndrome in IgA Multiple Myeloma. British Journal of Haematology, 1974, 27, 65-76.	2.5	26
234	Genetic and Laboratory Diagnosis. , 0, , 90-98.		2

#	Article	IF	Citations
235	Normal Haemostasis. , 0, , 783-807.		1
236	Miscellaneous Questions. , 0, , 206-206.		0